Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsLiquid Biopsy

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1157278

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1157278

Liquid Biopsy Market by Product (Assay Kits, Instruments), Circulating Biomarkers (CTC, ctDNA), Technology (NGS, PCR), Application (Cancer (Lung, Breast), Non-Cancer), Sample Type (Blood), End User (Reference Lab, Hospitals) - Global Forecast to 2027

PUBLISHED:
PAGES: 263 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

The global liquid biopsy market is projected to reach USD 10.0 billion by 2027 from USD 4.3 billion in 2022, at a CAGR of 18.3% during the forecast period. Market growth is driven by factors such as rising global prevalence of cancers and the growing need for early detection coupled with efficient treatment monitoring and recurrence detection is anticipated to support the growth of the global liquid biopsy market. Liquid biopsy also enables the detection of cancer recurrence at earlier than traditional diagnosis methods. Early diagnosis enabled by liquid biopsy tests help healthcare professionals to improve various cancer treatments. On the other hand, the lower sensitivity of certain liquid biopsies might act as a restraining factor to the growth of this market.

"The assay kits segment accounted for the highest growth rate in the liquid biopsy market, by product & service, during the forecast period"

The liquid biopsy market is segmented into assay kits, instruments, and services based on product & service. In 2021, the assay kits segment accounted for the highest growth rate in the liquid biopsy market. The accessibility of a wide range of reagents and kits and simple availability to a wide range of assays are the major factors driving the growth of the liquid biopsy assay kits market.

"Non-cancer applications segment accounted for the highest CAGR"

Based on application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2021, the non-cancer application segment accounted for the highest growth rate. This can be attributed to the increasing research activities in NIPT, organ transplant diagnosis and infectious diseases.

"Asia Pacific: The fastest-growing region liquid biopsy market"

The global liquid biopsy market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. The Asia Pacific region is projected to register the highest CAGR during the forecast period.

The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as increased healthcare spending by a larger population base, healthcare infrastructure modernization, and the rising penetration of cutting-edge clinical laboratory technologies (especially in rural areas). These factors are expected to provide significant growth opportunities for liquid biopsy companies operating in this region.

The APAC, which is becoming a medical tourism hub, is considered one of the fastest-growing markets for medical procedures and devices. Low infrastructure & treatment costs and the availability of highly educated physicians have driven medical tourists to APAC countries. This is a major factor driving the growth of the market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%sssss, and the Middle East & Africa - 4%

Lists of Companies Profiled in the Report:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Myriad Genetics, Inc. (US)
  • QIAGEN N.V. (Netherlands)
  • Thermo Fisher Scientific, Inc. (US)
  • Guardant Health, Inc. (US)
  • MDxHealth SA (Belgium)
  • Exact Sciences Corporation (US)
  • Illumina Inc. (US)
  • Sysmex Inostics (US)
  • Bio-Rad Laboratories, Inc. (US)
  • Biocept, Inc. (US)
  • NeoGenomics, Inc. (US)
  • ANGLE plc (UK)
  • Menarini-Silicon Biosystems (Italy)
  • Vortex Biosciences, Inc. (US)
  • Exosome Diagnostics, Inc. (US)
  • Agena Bioscience, Inc. (US)
  • MedGenome Inc. (US)
  • Epigenomics AG (Germany)
  • Personal Genome Diagnostics, Inc. (US)

Research Coverage:

This report provides a detailed picture of the global liquid biopsy market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, clinical application, technology, circulating biomarkers, application, and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall liquid biopsy market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Show more
Product Code: MD 4456

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 STUDY SCOPE
    • 1.3.1 LIQUID BIOPSY MARKET
    • 1.3.2 REGIONAL SCOPE
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • FIGURE 1 LIQUID BIOPSY MARKET: RESEARCH DESIGN METHODOLOGY
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
    • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
    • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation approach
    • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 CAGR projections
    • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
    • 2.3.2 TOP-DOWN APPROACH
    • FIGURE 6 LIQUID BIOPSY MARKET: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • 2.5 MARKET SHARE
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RISK ASSESSMENT
    • 2.8.1 RISK ASSESSMENT: LIQUID BIOPSY MARKET

3 EXECUTIVE SUMMARY

    • FIGURE 8 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 9 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 10 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
    • FIGURE 11 LIQUID BIOPSY MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 12 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2022 VS. 2027 (USD MILLION)
    • FIGURE 13 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2022 VS. 2027 (USD MILLION)
    • FIGURE 14 LIQUID BIOPSY MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
    • FIGURE 15 LIQUID BIOPSY MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)

4 PREMIUM INSIGHTS

  • 4.1 LIQUID BIOPSY MARKET OVERVIEW
    • FIGURE 16 RISING INCIDENCE OF CANCER TO DRIVE GROWTH IN LIQUID BIOPSY MARKET
  • 4.2 LIQUID BIOPSY MARKET SHARE, BY PRODUCT & SERVICE, 2022 VS. 2027
    • FIGURE 17 ASSAY KITS TO CONTINUE TO DOMINATE LIQUID BIOPSY MARKET DURING FORECAST PERIOD
  • 4.3 LIQUID BIOPSY MARKET SHARE, BY CIRCULATING BIOMARKER, 2022 VS. 2027
    • FIGURE 18 CIRCULATING TUMOR CELLS TO CONTINUE TO DOMINATE MARKET IN 2027
  • 4.4 LIQUID BIOPSY MARKET SHARE, BY CLINICAL APPLICATION, 2022 VS. 2027
    • FIGURE 19 THERAPY SELECTION SEGMENT TO HOLD LARGEST SHARE OF MARKET DURING FORECAST PERIOD
  • 4.5 LIQUID BIOPSY MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
    • FIGURE 20 MULTI-GENE PARALLEL ANALYSIS USING NGS SEGMENT TO HOLD LARGER SHARE OF MARKET IN 2027
  • 4.6 LIQUID BIOPSY MARKET SHARE, BY APPLICATION, 2022 VS. 2027
    • FIGURE 21 CANCER APPLICATIONS TO LEAD MARKET IN 2027
  • 4.7 LIQUID BIOPSY MARKET SHARE, BY SAMPLE TYPE, 2022 VS. 2027
    • FIGURE 22 BLOOD TYPE SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2027
  • 4.8 LIQUID BIOPSY MARKET SHARE, BY END USER, 2022 VS. 2027
    • FIGURE 23 REFERENCE LABORATORIES TO DRIVE MARKET GROWTH IN 2027
  • 4.9 LIQUID BIOPSY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 24 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN LIQUID BIOPSY MARKET DURING FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 25 LIQUID BIOPSY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence and prevalence of cancer
    • TABLE 1 NUMBER OF PREVALENT CANCER CASES WORLDWIDE IN 2020, BY TYPE OF CANCER
      • 5.2.1.2 Cancer awareness initiatives undertaken by global health organizations
      • 5.2.1.3 Increasing preference for non-invasive treatment procedures
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Lower sensitivity of certain liquid biopsy procedures
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growing significance of companion diagnostics
      • 5.2.3.2 Growth opportunities in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unclear reimbursement scenario
  • 5.3 PRICING ANALYSIS
    • TABLE 2 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT
    • TABLE 3 AVERAGE SELLING PRICE TREND
  • 5.4 PATENT ANALYSIS
    • FIGURE 26 PATENT ANALYSIS OF LIQUID BIOPSY
    • TABLE 4 PATENT ANALYSIS
  • 5.5 VALUE CHAIN ANALYSIS
    • FIGURE 27 MAJOR VALUE ADDITION DURING MANUFACTURING & ASSEMBLY PHASE
  • 5.6 SUPPLY CHAIN ANALYSIS
    • FIGURE 28 LIQUID BIOPSY MARKET: SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS OF LIQUID BIOPSY MARKET
    • FIGURE 29 LIQUID BIOPSY MARKET: ECOSYSTEM ANALYSIS
    • 5.7.1 LIQUID BIOPSY MARKET: ROLE IN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 5 LIQUID BIOPSY MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT FROM NEW ENTRANTS
    • 5.8.2 THREAT FROM SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 DEGREE OF COMPETITION
  • 5.9 REGULATORY LANDSCAPE
    • 5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 6 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 7 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 8 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 9 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.9.2 NORTH AMERICA
      • 5.9.2.1 US
      • 5.9.2.2 Canada
    • 5.9.3 EUROPE
    • 5.9.4 ASIA PACIFIC
      • 5.9.4.1 China
      • 5.9.4.2 Japan
    • 5.9.5 LATIN AMERICA
      • 5.9.5.1 Brazil
      • 5.9.5.2 Mexico
    • 5.9.6 MIDDLE EAST
    • 5.9.7 AFRICA
  • 5.10 TECHNOLOGY ANALYSIS
  • 5.11 PESTLE ANALYSIS
  • 5.12 TRADE ANALYSIS
    • 5.12.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
      • 5.12.1.1 Export scenario for liquid biopsy
    • TABLE 11 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
      • 5.12.1.2 Import scenario for liquid biopsy
    • TABLE 12 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (USD MILLION)
    • TABLE 13 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017-2021 (TONS)
  • 5.13 KEY CONFERENCES AND EVENTS IN 2022-2023
    • TABLE 14 LIQUID BIOPSY MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
    • 5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR LIQUID BIOPSY PRODUCT MANUFACTURERS
    • FIGURE 30 REVENUE SHIFT FOR LIQUID BIOPSY MARKET
  • 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • FIGURE 31 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
    • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF LIQUID BIOPSY PRODUCTS & SERVICES
    • 5.15.2 BUYING CRITERIA
    • FIGURE 32 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
    • TABLE 16 KEY BUYING CRITERIA FOR LIQUID BIOPSY PRODUCTS & SERVICES
  • 5.16 CASE STUDY ANALYSIS
    • 5.16.1 CASE STUDY 1
    • 5.16.2 CASE STUDY 2

6 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

  • 6.1 INTRODUCTION
    • TABLE 17 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
  • 6.2 ASSAY KITS
    • 6.2.1 RECURRENT REQUIREMENT AND PURCHASES OF ASSAY KITS TO DRIVE GROWTH
    • TABLE 18 KEY PRODUCTS IN ASSAY KITS MARKET
    • TABLE 19 LIQUID BIOPSY ASSAY KITS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.3 INSTRUMENTS
    • 6.3.1 LATEST ADVANCEMENTS IN PCR TECHNOLOGIES TO ENSURE MARKET GROWTH
    • TABLE 20 KEY PRODUCTS IN INSTRUMENTS MARKET
    • TABLE 21 LIQUID BIOPSY INSTRUMENTS MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 6.4 SERVICES
    • 6.4.1 INCREASING NUMBER OF LIQUID BIOPSY-BASED SERVICE DEVELOPMENTS TO SUPPORT MARKET GROWTH
    • TABLE 22 LIQUID BIOPSY SERVICES MARKET, BY REGION, 2020-2027 (USD MILLION)

7 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

  • 7.1 INTRODUCTION
    • TABLE 23 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
  • 7.2 CIRCULATING TUMOR CELLS (CTC)
    • 7.2.1 EASY COLLECTION AND PERSISTENT ASSESSMENT & ANALYSIS OF OVERALL TUMOR BURDEN TO DRIVE DEMAND
    • TABLE 24 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2020-2027 (USD MILLION)
  • 7.3 CIRCULATING TUMOR DNA (CTDNA)
    • 7.3.1 ABILITY OF CTDNA ANALYSIS TO SIGNIFICANTLY IMPROVE TUMOR DIAGNOSIS TO DRIVE MARKET
    • TABLE 25 LIQUID BIOPSY MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2020-2027 (USD MILLION)
  • 7.4 CELL-FREE DNA (CFDNA)
    • 7.4.1 GROWING APPLICATION OF CFDNA IN PRENATAL SCREENING TO DRIVE GROWTH
    • TABLE 26 LIQUID BIOPSY MARKET FOR CELL-FREE DNA, BY REGION, 2020-2027 (USD MILLION)
  • 7.5 EXTRACELLULAR VESICLES (EVS)
    • 7.5.1 ABILITY TO REMAIN STABLE IN BLOOD CIRCULATION OVER OTHER ANALYTES TO ENSURE CONSISTENT GROWTH IN MARKET
    • TABLE 27 LIQUID BIOPSY MARKET FOR EXTRACELLULAR VESICLES, BY REGION, 2020-2027 (USD MILLION)
  • 7.6 OTHER CIRCULATING BIOMARKERS
    • TABLE 28 LIQUID BIOPSY MARKET FOR OTHER CIRCULATING BIOMARKERS, BY REGION, 2020-2027 (USD MILLION)

8 LIQUID BIOPSY MARKET, BY TECHNOLOGY

  • 8.1 INTRODUCTION
    • TABLE 29 LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
  • 8.2 MULTI-GENE PARALLEL ANALYSIS USING NGS
    • 8.2.1 HIGH SENSITIVITY AND ECONOMICAL BENEFITS TO DRIVE GROWTH
    • TABLE 30 LIQUID BIOPSY MARKET FOR MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2020-2027 (USD MILLION)
  • 8.3 SINGLE-GENE ANALYSIS USING PCR MICROARRAYS
    • 8.3.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
    • TABLE 31 LIQUID BIOPSY MARKET FOR SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2020-2027 (USD MILLION)

9 LIQUID BIOPSY MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
    • TABLE 32 LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
  • 9.2 CANCER APPLICATIONS
    • TABLE 33 GLOBAL CANCER INCIDENCE, 2020 VS. 2040 (MILLION)
    • TABLE 34 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 35 LIQUID BIOPSY MARKET FOR CANCER APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • 9.2.1 LUNG CANCER
      • 9.2.1.1 Growing prevalence of lung cancer to propel market growth
    • TABLE 36 GLOBAL LUNG CANCER INCIDENCE, 2020 VS. 2040
    • TABLE 37 LIQUID BIOPSY MARKET FOR LUNG CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 9.2.2 BREAST CANCER
      • 9.2.2.1 Increasing government funding for breast cancer research to spur growth
    • TABLE 38 GLOBAL BREAST CANCER INCIDENCE, 2020 VS. 2040
    • TABLE 39 LIQUID BIOPSY MARKET FOR BREAST CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 9.2.3 COLORECTAL CANCER
      • 9.2.3.1 Rising prevalence of colorectal cancer to propel market
    • TABLE 40 GLOBAL COLORECTAL CANCER INCIDENCE, 2020 VS. 2040
    • TABLE 41 LIQUID BIOPSY MARKET FOR COLORECTAL CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 9.2.4 PROSTATE CANCER
      • 9.2.4.1 Growing number of prostate cancer patients to support market growth
    • TABLE 42 GLOBAL PROSTATE CANCER INCIDENCE, 2020 VS. 2040
    • TABLE 43 LIQUID BIOPSY MARKET FOR PROSTATE CANCER, BY REGION, 2020-2027 (USD MILLION)
    • 9.2.5 MELANOMA
      • 9.2.5.1 Growing need for early diagnosis of genetically mutated tumors to drive market growth
    • TABLE 44 GLOBAL MELANOMA INCIDENCE, 2020 VS. 2040
    • TABLE 45 LIQUID BIOPSY MARKET FOR MELANOMA, BY REGION, 2020-2027 (USD MILLION)
    • 9.2.6 OTHER CANCERS
    • TABLE 46 GLOBAL INCIDENCE OF OTHER CANCERS, 2020
    • TABLE 47 LIQUID BIOPSY MARKET FOR OTHER CANCERS, BY REGION, 2020-2027 (USD MILLION)
  • 9.3 NON-CANCER APPLICATIONS
    • TABLE 48 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
    • TABLE 49 LIQUID BIOPSY MARKET FOR NON-CANCER APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
    • 9.3.1 NON-INVASIVE PRENATAL TESTING (NIPT)
      • 9.3.1.1 Growing demand for NIPT in high-risk pregnancies to drive growth
    • TABLE 50 LIQUID BIOPSY MARKET FOR NIPT, BY REGION, 2020-2027 (USD MILLION)
    • 9.3.2 ORGAN TRANSPLANTATIONS
      • 9.3.2.1 Need for early detection of rejection to improve survival chances to drive growth
    • TABLE 51 LIQUID BIOPSY MARKET FOR ORGAN TRANSPLANTATIONS, BY REGION, 2020-2027 (USD MILLION)
    • 9.3.3 INFECTIOUS DISEASE TESTING
      • 9.3.3.1 Potential to reliably identify a wide variety of infections to drive adoption
    • TABLE 52 LIQUID BIOPSY MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2020-2027 (USD MILLION)

10 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

  • 10.1 INTRODUCTION
    • TABLE 53 LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
  • 10.2 THERAPY SELECTION
    • 10.2.1 GROWING PREFERENCE DUE TO NON-INVASIVENESS OF LIQUID BIOPSY TESTS TO DRIVE GROWTH
    • TABLE 54 LIQUID BIOPSY MARKET FOR THERAPY SELECTION, BY REGION, 2020-2027 (USD MILLION)
  • 10.3 TREATMENT MONITORING
    • 10.3.1 ABILITY TO QUANTITATIVELY CALCULATE CONCENTRATIONS OF CANCER-RELATED MUTATIONS TO FUEL DEMAND
    • TABLE 55 LIQUID BIOPSY MARKET FOR TREATMENT MONITORING, BY REGION, 2020-2027 (USD MILLION)
  • 10.4 RECURRENCE MONITORING
    • 10.4.1 ABILITY TO DETECT CANCER MUTATIONS THROUGH CTDNA TO DRIVE GROWTH
    • TABLE 56 LIQUID BIOPSY MARKET FOR RECURRENCE MONITORING, BY REGION, 2020-2027 (USD MILLION)
  • 10.5 EARLY CANCER SCREENING
    • 10.5.1 POTENTIAL OF LIQUID BIOPSY TO DETECT CANCER IN EARLY STAGES TO DRIVE MARKET
    • TABLE 57 LIQUID BIOPSY MARKET FOR EARLY CANCER SCREENING, BY REGION, 2020-2027 (USD MILLION)

11 LIQUID BIOPSY MARKET, BY SAMPLE TYPE

  • 11.1 INTRODUCTION
    • TABLE 58 LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 59 LIQUID BIOPSY SAMPLES AND APPLICATIONS
  • 11.2 BLOOD
    • 11.2.1 SIMPLE AND NON-INVASIVE NATURE TO DRIVE MARKET GROWTH
    • TABLE 60 LIQUID BIOPSY MARKET FOR BLOOD SAMPLES, BY REGION, 2020-2027 (USD MILLION)
  • 11.3 OTHER SAMPLE TYPES
    • TABLE 61 LIQUID BIOPSY MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2020-2027 (USD MILLION)

12 LIQUID BIOPSY MARKET, BY END USER

  • 12.1 INTRODUCTION
    • TABLE 62 LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 12.2 REFERENCE LABORATORIES
    • 12.2.1 INCREASING OUTSOURCING OF LIQUID BIOPSY TESTS TO REFERENCE LABORATORIES TO DRIVE GROWTH
    • TABLE 63 LIQUID BIOPSY MARKET FOR REFERENCE LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 12.3 HOSPITALS AND PHYSICIAN LABORATORIES
    • 12.3.1 GROWING NUMBER OF HOSPITALS WORLDWIDE TO BOOST GROWTH
    • TABLE 64 LIQUID BIOPSY MARKET FOR HOSPITALS AND PHYSICIAN LABORATORIES, BY REGION, 2020-2027 (USD MILLION)
  • 12.4 ACADEMIC & RESEARCH CENTERS
    • 12.4.1 GROWING FOCUS OF RESEARCH FOR DEVELOPMENT OF INNOVATIVE LIQUID BIOPSY TESTS TO FUEL GROWTH
    • TABLE 65 LIQUID BIOPSY MARKET FOR ACADEMIC & RESEARCH CENTERS, BY REGION, 2020-2027 (USD MILLION)
  • 12.5 OTHER END USERS
    • TABLE 66 LIQUID BIOPSY MARKET FOR OTHER END USERS, BY REGION, 2020-2027 (USD MILLION)

13 LIQUID BIOPSY MARKET, BY REGION

  • 13.1 INTRODUCTION
    • TABLE 67 LIQUID BIOPSY MARKET, BY REGION, 2020-2027 (USD MILLION)
  • 13.2 NORTH AMERICA
    • TABLE 68 NORTH AMERICA: NUMBER OF NEW CANCER CASES, BY TYPE OF CANCER, 2020
    • FIGURE 33 NORTH AMERICA: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 69 NORTH AMERICA: LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 70 NORTH AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 71 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 72 NORTH AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 73 NORTH AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 74 NORTH AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 75 NORTH AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 76 NORTH AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.2.1 US
      • 13.2.1.1 Increasing prevalence of cancer to drive growth
    • TABLE 77 US: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 78 US: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 79 US: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 80 US: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 81 US: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 82 US: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 83 US: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.2.2 CANADA
      • 13.2.2.1 Availability of various cancer screening programs to drive growth
    • TABLE 84 CANADA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 85 CANADA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 86 CANADA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 87 CANADA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 88 CANADA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 89 CANADA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 90 CANADA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 13.3 EUROPE
    • TABLE 91 EUROPE: LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 92 EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 93 EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 94 EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 95 EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 96 EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 97 EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 98 EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.1 GERMANY
      • 13.3.1.1 Favorable government health policies to support market growth
    • TABLE 99 GERMANY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 100 GERMANY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 101 GERMANY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 102 GERMANY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 103 GERMANY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 104 GERMANY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 105 GERMANY: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.2 UK
      • 13.3.2.1 Increasing number of diagnostic laboratories to propel market growth
    • TABLE 106 UK: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 107 UK: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 108 UK: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 109 UK: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 110 UK: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 111 UK: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 112 UK: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.3 FRANCE
      • 13.3.3.1 Rising R&D expenditure to drive market growth
    • TABLE 113 FRANCE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 114 FRANCE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 115 FRANCE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 116 FRANCE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 117 FRANCE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 118 FRANCE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 119 FRANCE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.4 ITALY
      • 13.3.4.1 Growing research on discovery of novel circulating cancer biomarkers to drive market growth
    • TABLE 120 ITALY: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 121 ITALY: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 122 ITALY: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 123 ITALY: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 124 ITALY: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 125 ITALY: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 126 ITALY: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.5 SPAIN
      • 13.3.5.1 Growing focus on personalized medicine to support market growth
    • TABLE 127 SPAIN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 128 SPAIN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 129 SPAIN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 130 SPAIN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 131 SPAIN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 132 SPAIN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 133 SPAIN: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.3.6 REST OF EUROPE
    • TABLE 134 REST OF EUROPE: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 135 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 136 REST OF EUROPE: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 137 REST OF EUROPE: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 138 REST OF EUROPE: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 139 REST OF EUROPE: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 140 REST OF EUROPE: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 13.4 ASIA PACIFIC
    • FIGURE 34 ASIA PACIFIC: LIQUID BIOPSY MARKET SNAPSHOT
    • TABLE 141 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 143 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 144 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 145 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 147 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 148 ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.4.1 CHINA
      • 13.4.1.1 Growing public access to advanced healthcare facilities to drive market
    • TABLE 149 CHINA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 150 CHINA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 151 CHINA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 152 CHINA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 153 CHINA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 154 CHINA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 155 CHINA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.4.2 JAPAN
      • 13.4.2.1 Universal healthcare reimbursement policy to fuel growth
    • TABLE 156 JAPAN: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 157 JAPAN: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 158 JAPAN: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 159 JAPAN: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 160 JAPAN: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 161 JAPAN: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 162 JAPAN: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.4.3 INDIA
      • 13.4.3.1 Increasing private & public investments in healthcare system to boost market
    • TABLE 163 INDIA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 164 INDIA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 165 INDIA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 166 INDIA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 167 INDIA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 168 INDIA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 169 INDIA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
    • 13.4.4 REST OF ASIA PACIFIC
    • TABLE 170 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 171 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 172 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 173 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 174 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 175 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 176 REST OF ASIA PACIFIC: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 13.5 LATIN AMERICA
    • 13.5.1 INCREASING PRIVATE & PUBLIC INVESTMENTS TO DRIVE MARKET
    • TABLE 177 LATIN AMERICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 178 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 179 LATIN AMERICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 180 LATIN AMERICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 181 LATIN AMERICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 182 LATIN AMERICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 183 LATIN AMERICA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)
  • 13.6 MIDDLE EAST & AFRICA
    • 13.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET GROWTH
    • TABLE 184 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE, 2020-2027 (USD MILLION)
    • TABLE 185 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2020-2027 (USD MILLION)
    • TABLE 186 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)
    • TABLE 187 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 188 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2020-2027 (USD MILLION)
    • TABLE 189 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2020-2027 (USD MILLION)
    • TABLE 190 MIDDLE EAST & AFRICA: LIQUID BIOPSY MARKET, BY END USER, 2020-2027 (USD MILLION)

14 COMPETITIVE LANDSCAPE

  • 14.1 OVERVIEW
  • 14.2 STRATEGIES OF KEY PLAYERS
    • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN LIQUID BIOPSY MARKET
    • TABLE 191 OVERVIEW OF STRATEGIES DEPLOYED BY KEY LIQUID BIOPSY COMPANIES
  • 14.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
  • 14.4 MARKET SHARE ANALYSIS
    • 14.4.1 LIQUID BIOPSY MARKET
    • FIGURE 36 LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER (2021)
    • TABLE 192 LIQUID BIOPSY MARKET SHARE: DEGREE OF COMPETITION
  • 14.5 COMPANY EVALUATION QUADRANT
    • 14.5.1 LIST OF EVALUATED VENDORS
    • 14.5.2 STARS
    • 14.5.3 EMERGING LEADERS
    • 14.5.4 PERVASIVE PLAYERS
    • 14.5.5 PARTICIPANTS
    • FIGURE 37 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
  • 14.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021)
    • 14.6.1 PROGRESSIVE COMPANIES
    • 14.6.2 STARTING BLOCKS
    • 14.6.3 RESPONSIVE COMPANIES
    • 14.6.4 DYNAMIC COMPANIES
    • FIGURE 38 LIQUID BIOPSY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
  • 14.7 COMPETITIVE BENCHMARKING
    • 14.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
    • FIGURE 39 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN LIQUID BIOPSY MARKET
    • TABLE 193 LIQUID BIOPSY MARKET: COMPANY GEOGRAPHICAL FOOTPRINT
    • TABLE 194 LIQUID BIOPSY MARKET: COMPANY PRODUCT & SERVICE FOOTPRINT
    • TABLE 195 LIQUID BIOPSY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • 14.8 COMPETITIVE SCENARIO
    • 14.8.1 PRODUCT LAUNCHES & APPROVALS
    • TABLE 196 KEY PRODUCT LAUNCHES & APPROVALS
    • 14.8.2 DEALS
    • TABLE 197 KEY DEALS

15 COMPANY PROFILES

  • (Business overview, Products offered, Recent Developments, MNM view)**
  • 15.1 KEY PLAYERS
    • 15.1.1 QIAGEN N.V.
    • TABLE 198 QIAGEN N.V.: BUSINESS OVERVIEW
    • FIGURE 40 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
    • 15.1.2 F. HOFFMANN-LA ROCHE AG
    • TABLE 199 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW
    • FIGURE 41 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021)
    • 15.1.3 MYRIAD GENETICS, INC.
    • TABLE 200 MYRIAD GENETICS, INC.: BUSINESS OVERVIEW
    • FIGURE 42 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.4 THERMO FISHER SCIENTIFIC, INC.
    • TABLE 201 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
    • FIGURE 43 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.5 GUARDANT HEALTH, INC.
    • TABLE 202 GUARDANT HEALTH, INC.: BUSINESS OVERVIEW
    • FIGURE 44 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.6 BIO-RAD LABORATORIES, INC.
    • TABLE 203 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
    • FIGURE 45 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.7 ILLUMINA, INC.
    • TABLE 204 ILLUMINA, INC.: BUSINESS OVERVIEW
    • FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.8 EXACT SCIENCES CORPORATION
    • TABLE 205 EXACT SCIENCES CORPORATION: BUSINESS OVERVIEW
    • FIGURE 47 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2021)
    • 15.1.9 SYSMEX INOSTICS (SUBSIDIARY OF SYSMEX CORPORATION)
    • TABLE 206 SYSMEX INOSTICS: BUSINESS OVERVIEW
    • FIGURE 48 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
    • 15.1.10 BIOCEPT, INC.
    • TABLE 207 BIOCEPT, INC.: BUSINESS OVERVIEW
    • FIGURE 49 BIOCEPT, INC.: COMPANY SNAPSHOT (2021)
    • 15.1.11 MDXHEALTH
    • TABLE 208 MDXHEALTH: BUSINESS OVERVIEW
    • FIGURE 50 MDXHEALTH: COMPANY SNAPSHOT (2021)
  • 15.2 OTHER PLAYERS
    • 15.2.1 NEOGENOMICS, INC.
    • 15.2.2 EPIGENOMICS AG
    • 15.2.3 ANGLE PLC
    • 15.2.4 MENARINI-SILICON BIOSYSTEMS
    • 15.2.5 VORTEX BIOSCIENCES, INC.
    • 15.2.6 EXOSOME DIAGNOSTICS, INC.
    • 15.2.7 MEDGENOME INC.
    • 15.2.8 AGENA BIOSCIENCE, INC.
    • 15.2.9 PERSONAL GENOME DIAGNOSTICS, INC.
    • 15.2.10 FREENOME HOLDINGS, INC.
    • 15.2.11 STRAND LIFE SCIENCES
    • 15.2.12 LUNGLIFE AI, INC.
    • 15.2.13 LUCENCE HEALTH INC.
    • 15.2.14 ANPAC BIO-MEDICAL SCIENCE CO., LTD.
  • *Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!